As the most frequently mutated oncogene across solid tumors, KRAS alterations are highly prevalent in major malignancies such as pancreatic ductal adenocarcinoma (up to 92%) and non-small cell lung cancer (30–40%), where they drive constitutive signaling and are broadly associated with adverse clinical outcomes [7,8,9]. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.